Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
Update: 2025-11-04
Description
Myriad Genetics' Q3 2025 results: Revenue matched expectations at $205.7M, but sales fell 3.6% YoY. Despite adjusted EBITDA surging 80% above estimates, operating margin dropped to -11.3%. MyRisk hereditary cancer test volumes surged 13% YoY, but stock plummeted 6% as investors grapple with slowing growth and increased competition.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
